source
- Bayer's asundexian receives FDA approval for stroke preventionBayer announced that the U.S. Food and Drug Administration has approved its oral anticoagulant asundexian for stroke prevention. The drug is indicated to lower the risk of subsequent stroke in pati…
- Delix Therapeutics raises $100M Series C to advance non-hallucinatory psychedelic for depressionDelix Therapeutics announced a $100 million Series C financing round, led by Johnson & Johnson’s venture arm JJDC and joined by investors such as SV Health Investors’ Dementia Discovery Fund, RA Ca…